Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06980103 · ClinicalTrials.gov registry record · NA
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
A NA study of Thyroid Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- NA
- Development phase
- 408
- Enrollment target
- 3
- Study locations
NCT06980103 is a NA study of Thyroid Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 408 participants, above the 273-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (49% higher). The trial reports 3 study locations across 2 states.
The verdict
NCT06980103, a NA study of Thyroid Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- NA
- Development phase
- 408 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment? - Does it help participants make choices that reflect what matters most to them? - How does the decision aid compare to usual care in supporting patients through this decision? Participants who have been recently diagnosed with intermediate-risk differentiated thyroid cancer (DTC) will be randomly assigned to one of two groups. One group will receive a special decision aid website. This site includes detailed information about RAI, short videos, drop-down menus with extra details, exercises to help clarify values, and tools to help patients prepare questions for their doctor. The other group will receive the American Cancer Society (ACS) website. This site gives basic information about RAI but does not include interactive tools and is not specific to intermediate-risk thyroid cancer. Follow up surveys will be sent to the participants periodically, first at the start of the study, and again at 1 week, 4 weeks, and 6 months later. Researchers will compare how the two groups differ in making informed decisions. The decision aid is meant to support, not replace, a conversation with the medical team. Doctor recommendations remain an important part of treatment decisions.
Conditions Studied
Interventions
- BEHAVIORAL Usual Care
- BEHAVIORAL Decision Aid
Study Locations (3)
District of Columbia
- Lombardi Comprehensive Cancer Center - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Virginia
- Inova Health System - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 408 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2029-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06980103
The ClinicalTrials.gov registry entry for NCT06980103 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 408 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (49% higher). The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.
NCT06980103 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Virginia.
Frequently Asked Questions
What is clinical trial NCT06980103 about?
NCT06980103 is a clinical study titled "Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer". The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment. The main questions it aims to answer are: - Does the decision aid help participants understand the risks and benefits of RAI treatment?...
What is the current status of trial NCT06980103?
This trial is currently recruiting. It is a NA study. The enrollment target is 408 participants. The study started on 2025-08-06. Estimated completion is 2029-07-31.
What conditions does trial NCT06980103 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT06980103?
The interventions under investigation include: Usual Care (BEHAVIORAL), Decision Aid (BEHAVIORAL).
Who is sponsoring clinical trial NCT06980103?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06980103 being conducted?
This trial has 3 study locations across District of Columbia, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
TRAIL Study: Feasibility and Pilot
RECRUITING · NA
-
Hereditary Risk Factors for Thyroid Cancer
RECRUITING · NA
-
Personalized Treatment in Thyroid Disorders
RECRUITING · NA
-
Assessing Patient Satisfaction and Confidence After Use of Educational Video to Augment Surgical Consent for Thyroid Surgery
RECRUITING · NA
-
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.